FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BioMed Realty Trust Inc 		2. Issuer Name and Ticker or Trading Symbol

Zosano Pharma Corp [ ZSAN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

17190 BERNARDO CENTER DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

1/30/2015
(Street)

SAN DIEGO, CA 92128
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   1/30/2015     C    64661   (1) A $9.35   518904   I   By BMV Direct SO LP   (2)
Common Stock   1/30/2015     P    26543   A $11.00   545447   I   By BMV Direct SO LP   (2)
Common Stock   1/30/2015     C    317409   (1) A $9.35   1896982   I   By BMV Direct SOTRS LP   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
8% Convertible Note Issued 9/9/13     (1) 1/30/2015     C         337150.19      (1) 3/31/2015   Common Stock   337150.19   $0.00   0   I   By BMV Direct SO LP   (2)
8% Convertible Note Issued 9/9/13     (1) 1/30/2015     C         1101393.09      (1) 3/31/2015   Common Stock   1101393.09   $0.00   0   I   By BMV Direct SOTRS LP   (3)
8% Convertible Note Issued 2/26/14     (1) 1/30/2015     C         267446.47      (1) 3/31/2015   Common Stock   267446.47   $0.00   0   I   By BMV Direct SO LP   (2)
8% Convertible Note Issued 2/26/14     (1) 1/30/2015     C         1148955.63      (1) 3/31/2015   Common Stock   1148955.63   $0.00   0   I   By BMV Direct SOTRS LP   (3)
8% Convertible Note Issued 12/2/14     (1) 1/30/2015     C         717437.19      (1) 3/31/2015   Common Stock   717437.19   $0.00   0   I   By BMV Direct SOTRS LP   (3)

Explanation of Responses:
( 1)  The outstanding principal and accrued interest on these Convertible Notes were automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at 85% of the Issuer's initial public offering price per share.
( 2)  BioMed Realty, L.P. (the "Partnership") is the sole general partner of BMV Direct SO LP. The sole general partner of the Partnership is BioMed Realty Trust, Inc. (the "REIT"). The REIT has sole voting and dispositive power with respect to the shares directly held by BMV Direct SO LP.
( 3)  BioMed Realty Holdings, Inc. ("Holdings") is the sole general partner of BMV Direct SOTRS LP. The sole shareholder of Holdings is the Partnership. The sole general partner of the Partnership is the REIT. The REIT has sole voting and dispositive power with respect to the shares directly held by BMV Direct SOTRS LP.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BioMed Realty Trust Inc
17190 BERNARDO CENTER DRIVE
SAN DIEGO, CA 92128
X

BioMed Realty L P
17190 BERNARDO CENTER DRIVE
SAN DIEGO, CA 92128
X


Signatures
Jonathan P.Klassen, Authorized Officer 2/2/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024 Zosano Pharma 차트를 더 보려면 여기를 클릭.
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024 Zosano Pharma 차트를 더 보려면 여기를 클릭.